References
- CriquiMHDenenbergJOLangerRDFronekAThe epidemiology of peripheral arterial disease: importance of identifying the population at riskVasc Med1997232212269546971
- RogerVLGoASLloyd-JonesDMHeart disease and stroke statistics – 2011 update: a report from the American Heart AssociationCirculation20111234e18e20921160056
- BeckwithCMungerMAEffect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarctionAnn Pharmacother19932767557668329800
- YusufSSleightPPogueJBoschJDaviesRDagenaisGHeart Outcomes Prevention Evaluation Study InvestigatorsEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med2000342314515310639539
- AhimastosAAWalkerPJAskewCEffect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trialJAMA2013309545346023385271
- AhimastosAADartAMLawlerABlomberyPAKingwellBAReduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patientsJ Hyperten200826510371042
- AhimastosAALatoucheCNatoliAKReddy-luthmoodooMGolledgeJKingwellBAPotential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudicationCir Res2014114711441155
- FujiyamaSMatsubaraHNozawaYAngiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivationCirc Res2001881222911139469
- HoghALindholtJSNielsenHJensenLPJohnsenSPUse of angiotensin-converting enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a nationwide propensity score matched follow-up studyVasc Endovascular Surg201246751552322843293
- ShahinYMazariFChetterIDo angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trialsInt J Surg20119320921321195215
- NorgrenLHiattWRDormandyJANehlerMRHarrisKAFowkesFGRTASC II Working GroupInter-society consensus for the management of peripheral arterial disease (TASC II)Eur J Vasc Endovasc Surg200733 Suppl 1S1S7517140820
- MargolisDJHoffstadOThomSThe differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetesWound Repair Regen201018544555120840518